Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q3 FY2023 Earnings Presentation
34 slides from Krishna Institute Of Medical Sciences's earnings presentation, Feb 9, 2023
Slide 1: Cover letter to stock exchanges: Investor presentation
09th February, 2023 The General Manager, The Manager, Department of Corporate services Listing Department Bombay Stock Exchange Ltd (BSE) National Stock Exchange of India Limited, Phiroze Jheejheebhoy Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No.C/1, 'G' Block, Mumbai - 400 001. Bandra -
Slide 2: Making Quality Healthcare Accessible & Affordable
MAKING QUALITY HEALTHCARE ACCESSIBLE & AFFORDABLE Private & Confidential
Slide 3: Driven by a Vision
Driven by a Vision Affordable Quality Care VISION: Best-in-Class Facilities Patient Centric Systems & Processes S To be the most preferred NT healthcare services brand by TIE providing affordable care and best PA clinical outcomes to patients. Clinical Outcome Driven Excellence And to be the best pl
Slide 4: Multi Specialty Care
Multi Specialty Care Brain Eyes Bones and Spine Radiology • Neurology • Ophthalmology • Orthopedics • Imaging • Neurosurgery Gastro Intestinal Tract • Arthroscopic Surgery • Interventional Radiology • Psychiatry • Medical Gastroenterology • Spine Surgery Lab Services • Neuro Rehabilitation • Surgica
Slide 5: KIMS at a Glance
KIMS at a Glance Telangana Secunderabad (1000) Maharashtra Paradise Circle (290) Nagpur (334) Kondapur (200) Nashik (Under Construction) Gachibowli (237) Andhra Pradesh Visakhapatnam (434) Srikakulam (200) Rajahmundry (195) Ongole (350) Kurnool (200) Nellore (250) Anantapur (250) Map not to scale 4
Slide 6: Dr. B. Bhaskar Rao - Visionary Behind KIMS
Dr. B. Bhaskar Rao - Visionary Behind KIMS Managing Director A legend in CT Surgery, Dr. Bollineni Bhaskar Rao {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio- Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. Well known i
Slide 7: Dr. Abhinay Bollineni
Dr. Abhinay Bollineni Chief Executive Officer Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. In a short span of 5 years, KIMS expanded and opened five additional units (
Slide 8: Board of Directors
Board of Directors Mr. Rajeswara Rao G Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Mrs. Anitha Dandamudi Shantanu Rastogi Independent Director, Managing Director Chief Executive Officer Whole-time Director Non-Executive Director Chairman (Stakeholders’ Relationship Committee) Mr. Saumen Chakrab
Slide 9: Shareholding Pattern - December 2022
Shareholding Pattern - 30 December, 2022 th Retail Pre IPO, Retail, 3.2% 8.6% Clearing Members, Promoter & Promoter 0.1% Group, 38.8% Share Holder No of Shares Share Holding % Category Promoter 31,086,304 38.84% General Atlantica 6,889,147 8.61% ICICI Ventures 1,939,393 2.42% FII, 11.9% Mirae Asset
Slide 10: Modern Medical Technology
Modern Medical Technology 4-Arm HD da Vinci O-Arm Scanner Spy Glass Fibroscan Robotic Surgical Multi-dimensional surgical State of the art add on to Specialized non-invasive System imaging platform optimized ERCP that allows doctors to diagnostic ultrasound-based Facilitates complex for use in spine
Slide 11: Many Firsts...
Many Firsts... • First in Asia in to do Trans catheter • India’s first COVID Double Lung • Number 1 in Nephrology treatments in Tricuspid Valve replacement transplant done in 2020 Andhra Pradesh* procedure done in 2018 • India’s first Breathing Lung transplant • Number 1 in Neurosurgery & Poly • Lar
Slide 12: Key Accomplishments
Key Accomplishments Pharmacie De Qualite (PDQ) ‘Best Patient Friendly Hospital’ ‘Best Hospital to Work For’ Certification Overall PDQ Evaluation Ranked No. 1 Hospital AHPI Health Care Excellence AHPI Global Conclave Performance Score - 98% by Times of India, Hyderabad Award (2017) Award (2019) Gradi
Slide 13: Consistent performer over 2 decades
Consistent performer over 2 decades (Rupees in Millions) 5,217 16,711 16,427** 4,203** 7% 11,287 7% 27. 32. R : R : A G G C C A 2,412 4,280 773 1,311 317 263 42 2005 2010 2015 2020 2022 9M-2023 2005 2010 2015 2020 2022 9M-2023 No. of No. of No. of No. of No. of No. of Hospitals: 1 Hospitals: 1 Hospi
Slide 14: Q3 Updates
Q3 Updates 13 Private & Confidential
Slide 15: Financial & Operational Highlights - 1/2
Financial & Operational Highlights - 1/2 (Rupees in Millions) FINANCIAL HIGHLIGHTS Q3 FY 23 Consolidated • From 1st September’22, M/s SPANV Medisearch Lifesciences Private Limited (Kingsway Hospital, Nagpur) has become subsidiary of “KIMS Hospitals”, post-acquisition of 51% stake. Therefore, Q3 FY23
Slide 16: Financial & Operational Highlights - 2/2
Financial & Operational Highlights - 2/2 FINANCIAL HIGHLIGHTS Q3 FY 23 Consolidated • Consolidated Revenue from operations grew by 42.8% YoY basis to Rs. 5,622 mn. • Consolidated Adjusted EBITDA (Excluding Other Income, INDAS adjustments, and one-off items) grew by 14% on a YoY basis to Rs. 1,470 mn
Slide 17: Digital & ESG Initiatives
Digital & ESG Initiatives DIGITAL INITIATIVES During the last quarter, KIMS continued its digitization journey with a goal of having 100% paperless business process in all its operational, clinical and finance verticals. As part of this journey, last quarter we have either initiated or delivered the
Slide 18: Group Operating Performance - 1/3
Group Operating Performance - 1/3 IP VOLUME (‘000) OP VOLUME (‘000) (1.7%) 1081 1.7% 137 132 1014 381 117 47 46 830 375 36 280 FY21 FY22 9M FY23 Q3 FY22 Q2 FY23 Q3 FY23 FY21 FY22 9M FY23 Q3 FY22 Q2 FY23 Q3 FY23 OCCUPANCY* ARPOB (‘000) 2.0% (6.1%) 29.8 78.6% 79.8% 82.2% 29.7 29.2 68.8% 72.6% 25.3 68.
Slide 19: Group Operating Performance - 2/3
Group Operating Performance - 2/3 (Rupees in Millions) TOTAL REVENUE (0.8%) EBITDA* (0.2%) 16,711 16,427 5,733 5,686 5,218 1,447 1,444 13,401 4,203 1,289 3,960 3,672 FY21 FY22 9M FY23 Q3 FY22 Q2 FY23 Q3 FY23 FY21 FY22 9M FY23 Q3 FY22 Q2 FY23 Q3 FY23 (8.0%) (10.3%) PBT# PAT# 4,569 1,226 3,438 912 1,1
Slide 20: Group Operating Performance - 3/3
Group Operating Performance - 3/3 (Rupees in Millions) Particulars FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 9M FY23 Bed Capacity 3,064 3,064 3,666 4,015 4,015 4,015 Operational Beds 2,590 2,590 3,222 3,543 3,543 3,543 Census Beds 2,246 2,246 2,760 3,026 3,026 3,026 Non Census Beds 344 344 462 517 517 517 O
Slide 21: Comparison of Telangana and Andhra Pradesh Matured Hospitals - 1/2
Comparison of Telangana and Andhra Pradesh Matured Hospitals - 1/2 (Rupees in Millions) Telangana (KIMS) AP Matured Assets Particulars FY21 FY22 Q1 FY 23 Q2 FY23 Q3 FY23 9M FY23 FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 9M FY23 Bed Capacity 1,200 1,200 1,200 1,200 1,200 1,200 630 630 630 645 645 645 Operati
Slide 22: Comparison of Andhra Pradesh Acquired, Sunshine & Nagpur - 2/2
Comparison of Andhra Pradesh Acquired, Sunshine & Nagpur - 2/2 (Rupees in Millions) AP Acquired Assets Sunshine Nagpur Group Particulars FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 9M FY23 Q1 FY23 Q2 FY23 Q3 FY23 9M FY23 Q2 FY23** Q3 FY23 FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 9M FY23 Bed Capacity 1234 1234 1234 1
Slide 23: Speciality Mix
Speciality Mix Others Cardiac Science 24% 18% Renal Sciences 9% Mother & Child 9% Group 9M FY 23 Organ Oncology Transplant 5% 2% Gastric Sciences 8% Neuro Sciences 12% Orthopaedics 14% Includes Sunshine and 4 months (Sep’22 - Dec'22) of Nagpur 22 Private & Confidential
Slide 24: Payor & Cluster Profile
Payor & Cluster Profile PAYOR MIX CLUSTER TOTAL REVENUE Maharashtra AP Mature 3.1% 10.9% Aarogyasri 8% AP Non Mature 15.9% Corporate Cash Group 12% 55% 9M FY23 Telangana 70.1% Group 9M FY23 CLUSTER EBITDA* Maharashtra AP Mature Insurance 0.6% 13.6% 25% AP Non Mature 12.1% Group 9M FY23 *EBITDA befor
Slide 25: Key Achievements in Q3 FY23
Key Achievements in Q3 FY23 24 Private & Confidential
Slide 26: Key Achievements in Q3 FY23
Key Achievements in Q3 FY23 25 Private & Confidential
Slide 27: Key to our success
Key to our success Doctor Affordable Partnerships Quality Care Modern Medical Infra 26 Private & Confidential
Slide 28: Disciplined growth strategy in adjacent markets
Kims has a disciplined growth strategy - strategically grow in adjacent markets some of which are ‘natural extensions’ KIMS Plans to Grow into Markets that are Adjacent to the Current Core Markets of AP and Telangana Central & Western India (Indore, Aurangabad, Nagpur & Raipur): KIMS flagship hospit
Slide 29: Update on Expansion Plans
Update on Expansion Plans 28 Private & Confidential
Slide 30: Future vision taking shape - Construction update
Future vision taking shape - Construction update KIMS-SUNSHINE KIMS HOSPITALS KIMS-MANAVATA KIMS-ICON GASTRO UNIT BEGUMPET BANGALORE NASHIK VISAKHAPATNAM 29 Private & Confidential
Slide 31: Expansion plans
Expansion plans Current Incremental New Approx. Approx. Timeline Units Beds Beds Departments Capex (Starting April 2021) Kondapur 200 500 All Specialities 300 Cr 36-42 months Vizag 434 50 Cancer Centre 15-20 Cr 36 months Cancer Centre / Anantapur 250 150 50-60 Cr 36-48 months Mother & Child Ongole 3
Slide 32: Profit and Loss Statement
Profit and Loss Statement (Rupees in Millions) Consolidated Particulars Q3 FY 23 Q2 FY 23 Q3 FY 22 QoQ(%) YoY(%) FY 22 FY 21 YoY(%) Operating Revenue 5,622 5,641 3,936 -0.3% 42.8% 16,508 13,299 24.1% Other Income 64 92 24 -29.9% 169.6% 203 102 99.3% Total Revenue 5,686 5,733 3,960 -0.8% 43.6% 16,711
Slide 33: Corporate Structure (As on 31 December 2022)
Corporate Structure (As on 31 December'22) st Krishna Institute of Medical Sciences Ltd. KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole (100%) (100%) (100%) (100%) AHPL KHEPL KIMS ICON KIMS Saveera KIMS Sarvejana KIMS-Manavata SPANV KIMS Hospitals Srikakulam Kondapur Vizag Anantapur Kur
Slide 34: Thank You
Thank You 33 Private & Confidential
Krishna Institute of Medical Sciences — Q3 FY2023 Earnings Presentation on 6ix